Wegovy: New Uses for Liver, Heart & Hormone Health

Introduction

You might know Wegovy (semaglutide) best as a powerful tool for weight loss. And while it certainly helps shed pounds, recent approvals and emerging real‑world use show it’s becoming much more than that.

Today, we’ll unpack the latest FDA approval for serious fatty liver disease (MASH), explore its existing role in heart health, and touch on intriguing benefits like reduced interference with oral HRT and birth control, widespread use around the world, and its expanding therapeutic potential.

If you want a simple, conversational explanation of how one medication is broadening horizons—this blog’s for you.

FDA Approval for MASH: Meeting a Bigger Health Need

Just this August 2025, the U.S. Food and Drug Administration (FDA) cleared Wegovy (semaglutide) for treating metabolic dysfunction-associated steatohepatitis (MASH)—a serious and progressive form of fatty liver disease that includes moderate to advanced fibrosis The Pharmaceutical Journal.

Why this matters:

MASH affects nearly 14.9 million U.S. adults, roughly 6% of the population Medical Xpress.
Wegovy is now the only GLP‑1 therapy approved for this indication, giving doctors a new, evidence‑based treatment option Medical Xpress.
Backed by clinical trials showing therapeutic effects on liver health, this marks a meaningful leap for liver care Medical Xpress.

Cardiovascular Benefits: Supporting Your Heart

Wegovy’s approval isn’t limited to weight and liver health:

In March 2024, the FDA added a new indication: Wegovy can now reduce the risk of cardiovascular death, heart attack and stroke in adults with established heart disease plus overweight or obesity, when used alongside diet and exercise U.S. Food and Drug Administration.
The SELECT trial, with over 17,000 participants, showed a 20% reduction in major adverse cardiovascular events (MACE)—such as heart attack or stroke—even in patients without diabetes Mass General Brigham.
Approvals now extend beyond the U.S., including the UK and Australia, where Wegovy is cleared to reduce heart attack and stroke risk in overweight/obese patients with cardiovascular disease The Guardian RACGP, and Canada similarly approved it for lowering the risk of nonfatal heart attacks Reuters.

Extra Benefits: Oral HRT, Birth Control & Widespread Use

While not often discussed, semaglutide (Wegovy) has proven helpful in these areas too:

Oral HRT and birth control pills: Semaglutide does not reduce the absorption of combined oral contraceptives (ethinylestradiol/levonorgestrel), meaning it’s unlikely to interfere with their effectiveness.
Global use: Over 22 million people worldwide take semaglutide in its various forms—Ozempic, Wegovy, or Rybelsus—making it one of the most prescribed medications in recent years.
Heart-health licensing: Beyond weight loss, Wegovy is officially licensed and used to prevent serious cardiovascular events, highlighting its role in holistic care—not just the scales Time Magazine.

What About Wegovy in the UK?

In the United Kingdom, Wegovy is approved by the MHRA (Medicines and Healthcare products Regulatory Agency) for weight management in adults with obesity or those who are overweight with at least one weight-related health condition, such as high blood pressure or type 2 diabetes.

In 2023, it became available through a controlled rollout via the NHS weight management services, and also privately through regulated clinics and online pharmacies. Since then, its popularity has grown rapidly.

Key points about Wegovy in the UK:

Licensed for use in weight loss and maintenance when combined with a reduced-calorie diet and increased physical activity
NICE (National Institute for Health and Care Excellence) supports its use in eligible patients for up to two years through the NHS
Increasing interest in its potential benefits for heart health and metabolic conditions, in line with global approvals

As UK regulators continue reviewing international data, it’s possible we may see expanded indications (like heart disease or liver disease) approved in the near future.

Quick Summary

Feature	What It Means for You
MASH Treatment	First GLP‑1 drug approved for moderate‑to‑advanced fatty liver disease—offers a targeted liver therapy.
Heart Protection	Shown to reduce risk of heart attack, stroke, and cardiovascular death—even in non-diabetic adults with heart disease.
Supports Oral HRT/Contraception	Doesn’t interfere with pill absorption—important for long-term hormonal treatments.
Trusted & Commonly Used	Over 22 million people worldwide use semaglutide—demonstrating broad acceptance and experience.
Licensed Cardio-Indication	Officially approved to support cardiovascular health, not just weight loss.

Conclusion

Wegovy (semaglutide) is no longer just a weight-loss injection. It’s a multifaceted therapy tackling major health issues like fatty liver and heart disease, all while supporting normal use of oral HRT and birth control.

With FDA approval for MASH and established cardiovascular benefits, it’s offering comprehensive care options for many. If you’re considering Wegovy or already using it, discussing these additional benefits with your healthcare provider might open up new avenues for managing your overall health.